Therefore, the understanding that LSEC do indeed promote T cell exhaustion at the fibrotic stage of HCC, and that many of these exhausted T cells express TIGIT, could lead to further investigations into the use of anti-TIGIT antibodies as an effective co-immunotherapy during advanced stages of fibrosis and cirrhosis to prevent or delay the progression of HCC. The gene discussed is TIGIT; the disease is hepatocellular carcinoma.